Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review

Sara J. Menown, Javier A. Tello*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)
19 Downloads (Pure)

Abstract

Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.
Original languageEnglish
Pages (from-to)5025–5045
Number of pages21
JournalAdvances in Therapy
Volume38
Issue number10
Early online date12 Sept 2021
DOIs
Publication statusPublished - 1 Oct 2021

Keywords

  • Menopause
  • Vasomotor symptoms
  • Hot flushes/flashes
  • Neurokinin 3 receptor antagonist
  • Fezolinetant
  • Elinzanetant (NT-814)
  • MLE4901
  • Serotonin Norepinephrine Reuptake Inhibitor
  • Venlafaxine
  • Desvenlafaxine

Fingerprint

Dive into the research topics of 'Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review'. Together they form a unique fingerprint.

Cite this